Starpharma Holdings Limited

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
Starpharma Holdings Limited (ASX: SPL, OTCQX:SPHRY), located in Melbourne Australia, is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical and life science applications.

Starpharma’s underlying technology is built around polylysine dendrimers – a precisely-defined synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical and medical uses. Starpharma has two core development portfolios: VivaGel® portfolio and DEP® drug delivery with the Company developing several products internally and others via commercial partnerships e.g. AstraZeneca, which allows an accelerated path to market and management of investment risk.

Starpharma’s novel DEP® platform has broad commercial applicability in drug delivery and is amenable to many therapy modalities including chemotherapeutic, radiotherapeutic or non-oncology drugs.
Ticker:
SPL
Exchange:
ASX
Company Type:
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Australia
Year Founded:
Not Provided
Main Therapeutic Focus:
Lead Product in Development:
DEP® docetaxel, DEP® cabazitaxel, DEP® irinotecan
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
VP Business Development
Starpharma Holdings Limited